Affymax, Inc.  

(Public, OTCMKTS:AFFY)   Watch this stock  
Find more results for AFFY
0.000 (0.00%)
Dec 19 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.08 - 1.17
Open     -
Vol / Avg. 0.00/196,394.00
Mkt cap 4.76M
P/E 1.77
Div/yield 0.05
EPS 0.07
Shares 37.49M
Beta 2.47
Inst. own 0%
Dec 22, 2014
Q3 2014 Affymax Inc Earnings Release (Estimated)
Sep 23, 2014
Affymax Inc Extraordinary Shareholders Meeting

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 17164.29% -1053.62%
Operating margin -2269.05% -1099.05%
EBITD margin - -2724.25%
Return on average assets 488.14% -22.96%
Return on average equity 2040.59% -420.95%
Employees 4 -
CDP Score - -


Suite 240, 19200 Stevens Creek Blvd
United States - Map
+1-650-8128700 (Phone)
+1-650-4240832 (Fax)

Website links


Affymax, Inc. is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a worldwide collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited (Takeda). As of December 31, 2011, over 2,600 patients have received peginesatide in clinical trials. As of December 31, 2011, The New Drug Application (NDA) for peginesatide is under review by the United States, Food and Drug Administration (FDA). As of December 31, 2011, the Company has suspended its development efforts to treat anemia in non-dialysis patients and chemotherapy-induced anemia.

Officers and directors

John A. Orwin Independent Chairman of the Board
Age: 49
Jonathan M. Couchman President, Chief Executive Officer, Director
Age: 43
Mark G. Thompson Chief Financial Officer
Age: 53
Grace U. Shin General Counsel
Age: 48